Repeat pull from proven relationships plus room left

AngioDynamics, Inc. (ANGO) — this company's answers

The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes existing customers/partners taking more on their own initiative, and that these relationships are lightly penetrated. Look for evidence. From transcript: Jim Clemmer mentions NanoKnife growth, international growth, Auryon growth, etc. But specifically about existing relationships deepening? For example, Auryon: "we have also, as we've talked about in the past, seen a lot of shifting of lasers from some of the lower volume users and moving into higher volume users." That suggests existing customers using more? But is that on their own initiative? It's about shifting lasers to higher volume users, which might be placements, not necessarily existing customers taking more. Also "we were going to pair back a little bit on buying the new systems and the cash utilization that goes along with that, but we're going to focus on driving utilization" - that suggests they are focusing on increasing utilization of existing installed base, which could be existing customers using more. But does management explicitly say that existing customers are taking more on their own initiative? They mention "physician feedback" and "physicians, their peers that use it, talk about great outcomes" - that's more about adoption. For NanoKnife: "Our NanoKnife business performed very well and grew approximately 36% during the first quarter, with sales of probes growing 35%. NanoKnife growth was strong again internationally, as our international team continues to establish new relationships with partners who assist in supporting our procedures and our strong U.S. growth was driven by continuing interest in this technology as more physicians become aware of our direct and preserved trials." That seems to be new relationships and new physicians, not necessarily existing customers deepening. For Auryon: "We continue to gain share because physicians are gaining confidence in our technology" - that could be existing users using more, but not explicit. For mechanical thrombectomy: AngioVac "declined roughly 6% year-over-year. We were encouraged to see that AngioVac revenues while down year-over-year, grew sequentially, and we believe that the steps we are taking to drive this business are gaining positive traction." That's about recovery, not expansion.

← Back to the full ANGO analysis